Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pease

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Jvs-Vascular Science|October 7, 2021
Transglutaminase 2 moderates the expansion of mouse abdominal aortic aneurysmsKathryn J Griffin, Kingsley R Simpson, Cora M L Beckers, et al.
Diabetes & Vascular Disease Research|January 19, 2012
Complement C3 is a novel plasma clot component with anti-fibrinolytic propertiesJoanna-Marie Howes, Victoria R Richardson, Kerrie A Smith, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2003
Indole amide hydroxamic acids as potent inhibitors of histone deacetylasesYujia Dai, Yan Guo, Jun Guo, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 10, 2017
Cre/lox Studies Identify Resident Macrophages as the Major Source of Circulating Coagulation Factor XIII-ACora M L Beckers, Kingsley R Simpson, Kathryn J Griffin, et al.
Atherosclerosis|December 25, 2019
Transglutaminase 2 limits the extravasation and the resultant myocardial fibrosis associated with factor XIII-A deficiencyKathryn J Griffin, Laura M Newell, Kingsley R Simpson, et al.
World Neurosurgery|October 22, 2022
Intraoperative Sensory Signals Predict Prognosis for Patients with Traumatic Cervical Spinal Cord InjuryJohn R Renehan, Ivan B Ye, Alexandra E Thomson, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Trifluoromethyl ketones as inhibitors of histone deacetylaseRobin R Frey, Carol K Wada, Robert B Garland, et al.
The FEBS Journal|June 24, 2018
Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasiaIvana Mižíková, Tilman Pfeffer, Claudio Nardiello, et al.
Molecular Cancer Therapeutics|March 16, 2019
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell LymphomaNicolas Floc'h, Susan Ashton, Douglas Ferguson, et al.
Molecular Cancer Therapeutics|March 16, 2017
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 NanoparticlesNicolas Floc'h, Susan Ashton, Paula Taylor, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Jvs-Vascular Science|October 7, 2021
Transglutaminase 2 moderates the expansion of mouse abdominal aortic aneurysmsKathryn J Griffin, Kingsley R Simpson, Cora M L Beckers, et al.
Diabetes & Vascular Disease Research|January 19, 2012
Complement C3 is a novel plasma clot component with anti-fibrinolytic propertiesJoanna-Marie Howes, Victoria R Richardson, Kerrie A Smith, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2003
Indole amide hydroxamic acids as potent inhibitors of histone deacetylasesYujia Dai, Yan Guo, Jun Guo, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 10, 2017
Cre/lox Studies Identify Resident Macrophages as the Major Source of Circulating Coagulation Factor XIII-ACora M L Beckers, Kingsley R Simpson, Kathryn J Griffin, et al.
Atherosclerosis|December 25, 2019
Transglutaminase 2 limits the extravasation and the resultant myocardial fibrosis associated with factor XIII-A deficiencyKathryn J Griffin, Laura M Newell, Kingsley R Simpson, et al.
World Neurosurgery|October 22, 2022
Intraoperative Sensory Signals Predict Prognosis for Patients with Traumatic Cervical Spinal Cord InjuryJohn R Renehan, Ivan B Ye, Alexandra E Thomson, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Trifluoromethyl ketones as inhibitors of histone deacetylaseRobin R Frey, Carol K Wada, Robert B Garland, et al.
The FEBS Journal|June 24, 2018
Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasiaIvana Mižíková, Tilman Pfeffer, Claudio Nardiello, et al.
Molecular Cancer Therapeutics|March 16, 2019
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell LymphomaNicolas Floc'h, Susan Ashton, Douglas Ferguson, et al.
Molecular Cancer Therapeutics|March 16, 2017
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 NanoparticlesNicolas Floc'h, Susan Ashton, Paula Taylor, et al.
Pageof 12